Clinical efficacy of dapagliflozin/metformin and pioglitazone in type 2 diabetes mellitus with metabolic-associated fatty liver disease
LIN Qiuqiao
WANG Qunyou
LI Dan
LIAO Qingjuan
DUAN Xin
Abstract：Objective To observe the therapeutic effect of dapagliflozin/metformin and pioglitazone in type 2 diabetes mellitus(T2DM)with metabolic-associated fatty liver disease(MAFLD).Methods A total of 110 patients with T2DM and MAFLD in Dongguan KangHua Hospital from December 2023 to April 2024 were treated with dapagliflozin/metformin(control group)or dapagliflozin/metformin plus pioglitazone(observation group).The islet function,blood glucose,blood lipid,inflammatory factors,liver indexes and adverse reactions were compared between two groups.Results Compared with control group,islet β resistance index,total cholesterol,triglyceride,tumor necrosis factor-α,interleukin-1β,hypersensitive C-reactive protein,alanine/aspartate aminotransferases,blood glucose,glycosylated hemoglobin,liver stiffness and liver fat content were significantly decreased,while islet β secretion function index increased in observation group(P<0.01 or 0.05).There was no significant difference in the overall incidence of adverse reactions between two groups(P>0.05).Conclusion The combined use of dapagliflozin/metformin and pioglitazone can not only improve the islet function,blood lipid,liver function and blood glucose,but also reduce inflammatory factors,liver stiffness and liver fat content in T2DM patients with MAFLD.
Keywords：type 2 diabetes mellitusmetabolic-associated fatty liver diseasedapagliflozin/metforminpioglitazone
Publication Date：2024-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 624-627 )